AngioDynamics (ANGO) 10-Q2024 Q3 Quarterly report

Filed: 9 Apr 24, 5:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abandon, abandonment, Ablation, admitted, BD, Becton, building, CAFC, closure, counterclaimed, Dickinson, face, Feb, final, footprint, fundamentally, line, lump, Midline, milestone, mutual, parent, percent, PICC, plant, profile, RadioFrequency, ratably, recall, reply, RF, settlement, Spectrum, sue, sum, VA

Removed: art, asserted, began, beginning, belief, bifurcated, close, commenced, conference, December, defendant, disposed, eligibility, estimable, expectation, ineligible, infringed, invalid, invalidated, invalidating, jury, law, lifted, matter, motion, naked, occurrence, oral, proceeded, reexamination, remand, remanded, resolution, reversed, scheduled, scheduling, sourced, stay, stayed, supportable, Trademark, translation, trial, upheld, USC, USPTO, vacated, verdict, willfully

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ANGO transcripts

ANGO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO TITLE 18,

UNITED STATES CODE, SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James C. Clemmer, President, Chief Executive Officer and Director of ANGIODYNAMICS, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that, to the best of my knowledge:


1.						the quarterly report on Form 10-Q of the Company for the fiscal quarter ended February 29, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.						the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 9, 2024


/ S / JAMES C. CLEMMER
James C. Clemmer, President, Chief Executive Officer